期刊
ONCOTARGET
卷 7, 期 12, 页码 13446-13463出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7178
关键词
aptamers; SELEX; siRNA; cancers; target therapy
资金
- Sydney Medical Foundation, University of Sydney
- Cancer Council NSW grant [APP1070076]
- NHMRC [1053206, 632630, 1049857]
- Sydney West Translational Cancer Research Centre - Cancer Institute NSW
Aptamers, also known as chemical antibodies, are single-stranded nucleic acid oligonucleotides which bind to their targets with high specificity and affinity. They are typically selected by repetitive in vitro process termed systematic evolution of ligands by exponential enrichment (SELEX). Owing to their excellent properties compared to conventional antibodies, notably their smaller physical size and lower immunogenicity and toxicity, aptamers have recently emerged as a new class of agents to deliver therapeutic drugs to cancer cells by targeting specific cancer-associated hallmarks. Aptamers can also be structurally modified to make them more flexible in order to conjugate other agents such as nano-materials and therapeutic RNA agents, thus extending their applications for cancer therapy. This review presents the current knowledge on the practical applications of aptamers in the treatment of a variety of cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据